Singapore markets open in 3 hours 34 minutes

Cell Source, Inc. (CLCS)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
0.00080.0000 (0.00%)
At close: 12:54PM EDT

Cell Source, Inc.

57 West 57th Street
Suite 400
New York, NY 10019
United States
646 416 7896

Full-time employees1

Key executives

NameTitlePayExercisedYear born
Dr. Dennis M. Brown B.Sc., M.A., Ph.D.Executive ChairmanN/AN/A1950
Mr. Itamar ShimratCEO, President & CFO208.09kN/A1959
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was incorporated in 2012 and is headquartered in New York, New York.

Corporate governance

Cell Source, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.